Therapeutics and Biomaterials
The emergence of antibiotic resistance has severely reduced the effectiveness of all antibiotics that are clinically used today. At the same time, very few fundamentally new antibiotics have been developed in the past 20 years.
Consequently, we are rapidly running out of treatment options for resistant infections. Development of new lead compounds is a difficult, high-risk problem that requires a multidisciplinary approach.
In collaboration with health care and industry CARe works to identify new treatment options and to develop new antibiotic substances.